Recent RPTX Stock Price | RPTX Stock Predictions | |
$3.20 | +379.06% |
$15.33 |
Recent RPTX Analyst Ratings Breakdown, Making RPTX Stock Predictions | ||||
---|---|---|---|---|
Current | 1 Mo. Ago | 2 Mo. Ago | 3 Mo. Ago | |
Strong buy ratings: | 6 | 5 | 5 | 6 |
Buy ratings: | 0 | 1 | 1 | 0 |
Hold ratings: | 1 | 1 | 1 | 1 |
Sell ratings: | 0 | 0 | 0 | 0 |
Strong sell ratings: | 0 | 0 | 0 | 0 |
Average rating: | 1.29 | 1.43 | 1.43 | 1.29 |
For the RPTX stock predictions from the analysts covering Repare Therapeutics Inc, we have collected all of the individual RPTX stock predictions for stock price one year from now (i.e. each analyst's "forward price target") and at the top of this page we have presented the average prediction across the 6 different analysts covering RPTX (as reported in
data provided by Zacks Investment Research via Quandl.com).
But since RPTX stock predictions may vary widely, another useful metric to consider is the median RPTX stock prediction, which represents the price at which half of the analysts
made RPTX stock predictions that were higher and half made RPTX stock predictions that were lower. This makes for a different take on the RPTX stock predictions out there, as compared to average or mean.
And that median across all the individual RPTX stock predictions was: $14.0 as of 2024-04-29.
The very highest of the RPTX stock predictions for one year price target was $25.0, while the very lowest of the RPTX stock predictions in the analyst group was
$8.0 (with a standard deviation of $6.531). Get the latest Zacks research report on RPTX — FREE
Dividend Growth Stocks: 25 Aristocrats
10 Dividend Bargains You Can Buy Cheaper Than Insiders Did
Other stock predictions:
BGS Stock Predictions
QMCO Stock Predictions
CUB Stock Predictions
EGOV Stock Predictions
SNAP Stock Predictions
LCI Stock Predictions
HBIO Stock Predictions
AVDL Stock Predictions
MXIM Stock Predictions
|
|
Strong Buy (3.71 out of 4) 70th percentile
(ranked higher than approx. 70% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |